Relapsed or refractory multiple myeloma refers to disease that returns after previous therapy or does not respond adequately to ongoing therapy. When this happens, care teams typically reassess the treatment plan, review all drugs the patient has already received, and consider newer targeted and cellular options. The goal is disease control, maintaining quality of life, and prolonging time between recurrences through evidence-based sequencing of available therapies. Guidance in this area changes frequently because multiple myeloma therapies continue to evolve at a rapid pace, including immunotherapies and cell-based approaches.
Relapsed disease and refractory disease are often discussed together in current guidelines because many patients have already received combinations of proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies in the first line or early lines of therapy. The term “relapsed and or refractory multiple myeloma” therefore appears in clinical discussions of the current treatment landscape for relapsed and or refractory multiple myeloma. In practice, selection of the next regimen depends on which drug classes the disease is still sensitive to, and on patient-specific medical considerations such as age, organ function, previous toxicities, and access to specialized therapies.
Relapse describes myeloma that initially responded to treatment but later showed signs of progression again, such as rising monoclonal protein or new lesions. Refractory disease describes myeloma that either never reached a meaningful response on a given regimen or progressed while still on that regimen. These distinctions matter because they help determine eligibility for certain agents and combinations laid out in relapsed refractory multiple myeloma treatment guidelines. Patients whose disease is refractory to a specific class, such as lenalidomide, are often steered toward an alternative class in the next line rather than repeating a similar mechanism.
The overall objective of a relapsed myeloma plan is not limited to immediate response. It also includes preserving future options. This is why clinicians often consider whether to re-use a prior drug class that previously worked, switch to a new triplet or quadruplet regimen, or move toward cellular or antibody-based immunotherapy. The discussion about Best treatment options for relapsed multiple myeloma usually includes response depth, expected duration of control, safety profile, prior exposure, and logistics such as infusion requirements or monitoring needs.
The current treatment landscape for relapsed and or refractory multiple myeloma includes several major categories: proteasome inhibitors (such as bortezomib or carfilzomib), immunomodulatory drugs (such as lenalidomide or pomalidomide), anti-CD38 monoclonal antibodies (such as daratumumab or isatuximab), antibody-drug conjugates directed at B-cell maturation antigen (BCMA), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Many modern regimens combine three or more of these agents along with dexamethasone. Contemporary relapsed refractory multiple myeloma treatment guidelines emphasize that regimen choice should reflect which classes the myeloma remains sensitive to and which classes it has become refractory to.
When disease returns after first-line therapy, especially after lenalidomide-based maintenance, clinicians often consider triplet regimens that include a proteasome inhibitor plus an anti-CD38 antibody plus dexamethasone, or an immunomodulatory drug plus an anti-CD38 antibody plus dexamethasone. According to guideline summaries, combinations such as daratumumab with a proteasome inhibitor backbone or isatuximab-based triplets appear as recommended options for patients whose disease is refractory to lenalidomide. In this setting, the question of Relapsed multiple myeloma treatment after first-line therapy focuses on regimens that can overcome lenalidomide resistance while maintaining tolerability.
For patients with later relapse, treatment plans may incorporate drugs like pomalidomide or carfilzomib, either re-using previously tolerated classes or rotating to a different class if resistance emerged. These multidrug regimens aim to re-establish control of the disease and delay further progression, while monitoring for known class-related effects such as neuropathy with some proteasome inhibitors or cardiovascular effects with certain proteasome inhibitors. This approach reflects the structured, stepwise escalation described in relapsed refractory multiple myeloma treatment guidelines and helps maintain a sequence of options over multiple relapses.
Targeted therapies for relapsed multiple myeloma now include BCMA-directed agents, which recognize the B-cell maturation antigen found on myeloma cells. Antibody-drug conjugates such as belantamab mafodotin deliver a cytotoxic payload directly to BCMA-expressing plasma cells. Belantamab mafodotin (also known as Blenrep) was first granted accelerated approval in 2020 for relapsed or refractory multiple myeloma, was later voluntarily withdrawn in the United States after confirmatory trial results did not meet certain requirements, and has since re-entered regulatory review and received new combination approvals in regions such as the United Kingdom for previously treated patients. These developments illustrate how targeted antibody-drug conjugates remain part of Advanced treatments for relapsed multiple myeloma patients, particularly for individuals who have already received multiple standard classes.
Bispecific antibodies represent another targeted strategy. These laboratory-designed antibodies bind BCMA on myeloma cells and CD3 on T cells at the same time, redirecting the patient’s own immune cells toward the cancer. Teclistamab (Tecvayli) became the first bispecific BCMA-directed CD3 T-cell engager to receive U.S. Food and Drug Administration authorization for adults with relapsed or refractory multiple myeloma who previously received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Later regulatory updates allowed adjustments such as less frequent dosing in certain responders, reflecting efforts to balance ongoing disease control with long-term safety and convenience.
CAR T-cell therapy is a form of personalized immunotherapy in which a patient’s own T cells are collected, genetically modified to recognize a target such as BCMA, expanded, and then reinfused. Two BCMA-directed CAR T-cell products, idecabtagene vicleucel and ciltacabtagene autoleucel, have received FDA approvals for adults with relapsed or refractory multiple myeloma after prior lines of therapy that typically include a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. These products were initially positioned for heavily pretreated patients but more recent regulatory actions have moved them into earlier treatment lines, including use after one or two prior regimens in some cases, showing how the label indications have shifted toward earlier relapse.
These cell-based products are frequently listed as preferred options in later lines within major relapsed refractory multiple myeloma treatment guidelines because they can produce deep responses in patients whose disease has already been exposed to multiple drug classes. CAR T-cell therapy requires specialized centers, careful monitoring for cytokine release syndrome and neurologic events, and evaluation of organ function. However, it is considered among the Advanced treatments for relapsed multiple myeloma patients and is often discussed when conventional triplets or quadruplets are no longer effective.
In addition to teclistamab, newer bispecific antibodies are being studied or have recently gained authorization. Linvoseltamab (also referred to as linvoseltamab-gcpt) is a BCMA-directed, CD3-engaging bispecific antibody that received authorization in the European Union in April 2025 and U.S. approval in July 2025 for adults with relapsed or refractory multiple myeloma. This illustrates how BCMA remains a central target in the modern myeloma toolbox.
Research is also evaluating bispecific antibodies that act on non-BCMA targets. Cevostamab is designed to engage CD3 on T cells and FcRH5 on myeloma cells, and is being studied for patients who are “triple-class refractory,” meaning they are refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and in some cases have already received BCMA-directed therapy. These agents are relevant to the discussion of Targeted therapies for relapsed multiple myeloma because they aim to direct the immune system against myeloma cells even when traditional drug classes have been exhausted.
Relapsed refractory multiple myeloma treatment guidelines, including those published by groups such as the National Comprehensive Cancer Network (NCCN), recommend that treatment selection account for prior drug exposure, resistance patterns, time since last therapy, patient performance status, and practical considerations such as transplant eligibility and access to cellular therapy centers. These guidelines are updated frequently. Experts involved in these guidelines have noted that the multiple myeloma treatment paradigm is changing quickly with the introduction of novel quadruplet regimens, maintenance strategies, and earlier use of advanced immunotherapies, and therefore clinicians are encouraged to review updated versions regularly.
Another concept in guideline-directed care is sequencing. After first relapse, triplet or quadruplet antibody-based regimens are often prioritized. After two or more relapses, or in cases of rapid biochemical progression despite recent therapy, CAR T-cell therapy or a bispecific antibody may be considered if the patient meets eligibility criteria. This structured escalation supports a rational path through available options rather than relying on unplanned switches.
Each class used in relapsed and refractory multiple myeloma has known safety requirements. For example, BCMA-directed CAR T-cell therapy and bispecific antibodies such as teclistamab can be associated with immune-related side effects, including cytokine release syndrome and neurologic events, so observation in experienced centers is standard. Belantamab mafodotin requires eye monitoring because of the risk of corneal changes, and proteasome inhibitors can require monitoring for nerve-related or cardiovascular effects depending on the agent. These considerations are part of treatment planning and often influence whether a regimen is suitable for a given individual.
Access and logistics also influence choice. CAR T-cell therapy involves cell collection, manufacturing, lymphodepleting chemotherapy, and hospitalization or close monitoring after infusion. Bispecific antibodies are typically administered in repeated doses, sometimes weekly at first and later every two weeks for patients who maintain certain response levels, as seen with the updated dosing guidance for teclistamab. Such differences inform discussions about which option aligns with the patient’s health status and practical ability to receive frequent monitoring.
Research continues to evaluate combinations that integrate established backbones with new targeted components. For instance, updated analyses have examined belantamab mafodotin in combination with bortezomib and dexamethasone or with pomalidomide and dexamethasone in previously treated myeloma, and regulators in some regions have granted new combination approvals for adult patients who have undergone at least one prior therapy. Investigators are also studying how early to introduce CAR T-cell therapy and bispecific antibodies, and whether rotating between BCMA-targeted approaches and non-BCMA targets such as FcRH5 can extend disease control in heavily pretreated populations.
The field of relapsed and refractory multiple myeloma is moving from traditional chemotherapy-style sequencing toward highly specific immune and cellular strategies. The Best treatment options for relapsed multiple myeloma are now determined by careful matching of prior exposure, resistance status, and eligibility for advanced platforms such as CAR T-cell therapy or bispecific antibodies. As a result, discussions about Advanced treatments for relapsed multiple myeloma patients increasingly include targeted therapies for relapsed multiple myeloma, CAR T-cell therapy, and emergent bispecific antibodies, alongside established triplet or quadruplet regimens for Relapsed multiple myeloma treatment after first-line therapy. Continual reference to updated relapsed refractory multiple myeloma treatment guidelines helps ensure that each treatment decision is backed by current evidence, regulatory status, and practical feasibility.